SCHEMBL16394238

SCHEMBL16394238

CC1(C)CCNc2cc(Nc3nc4c(N5CCC6(CC5)CNC(=O)C6)nccn4n3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 14/20 0.48
▸ JAK2 O60674 11/20 0.48
▸ SYK P43405 1/20 0.40
▸ EIF2AK4 Q9P2K8 1/20 0.40
▸ WEE1 P30291 1/20 0.40
▸ PLK1 P53350 1/20 0.40
▸ JAK3 P52333 4/20 0.39
▸ CYP11B1 P15538 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ TYK2 P29597 5/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ IGF1R P08069 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16394735 0.95 JAK1 (0.49) JAK1JAK2SYKEIF2AK4WEE1
SCHEMBL16394558 0.95 JAK1 (0.49) JAK1JAK2SYKEIF2AK4WEE1
SCHEMBL15221254 0.95 JAK1 (0.49) JAK1JAK2SYKEIF2AK4WEE1
SCHEMBL16394650 0.88 JAK2 (0.47) JAK1JAK2SYKEIF2AK4JAK3
SCHEMBL15210965 0.85 JAK2 (0.48) JAK1JAK2SYKEIF2AK4WEE1
SCHEMBL15221134 0.85 JAK1 (0.43) JAK1JAK2SYKEIF2AK4WEE1
SCHEMBL15210425 0.83 JAK1 (0.48) JAK1JAK2SYKEIF2AK4JAK3
SCHEMBL15210533 0.83 JAK1 (0.48) JAK1JAK2SYKEIF2AK4JAK3
SCHEMBL15210476 0.83 JAK1 (0.48) JAK1JAK2SYKEIF2AK4JAK3
SCHEMBL16394439 0.81 JAK1 (0.41) JAK1JAK2SYKEIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 — — EP claimed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 — — US claimed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 — — US claimed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 — — EP disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 — — EP disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 — — US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS SYK, EIF2AK4, BTK JAK1 27/4885JAK2 29/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback